Business
CervoMed’s neflamapimod elected for inclusion in UK EXPERTS-ALS platform designed to prioritize promising treatments for Amyotrophic Lateral Sclerosis
Neflamapimod endorsement based on targeted mechanism of action, demonstrated clinical activity in neurodegenerative diseases, and encouraging translational
About this update from Cervomed Inc.
[{"type":"text","content":"Neflamapimod endorsement based on targeted mechanism of action, demonstrated clinical activity in neurodegenerative diseases, and encouraging translational data in ALS-relevant neurotoxicity models UK-based trial first to evaluate neflamapimod in ALS; first person with ALS expected to be dosed by end of 2026 Trial costs funded by United Kingdom government and leading motor neuron disease charities BOSTON, Feb. 18, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders, today announced that neflamapimod, an oral small molecule drug candidate targeting critical disease processes underlying degenerative disorders of the brain, has been selected for inclusion in the EXPERTS-ALS platform. EXPERTS-ALS facilitates rapid testing of potential treatments for amyotrophic lateral sclerosis (ALS) to identify promising drug candidates and potentially accelerate their path to regulatory approval. Funded by the United Kingdom (UK) National Institute for Health and Care Research (NIHR) and leading motor neuron disease charities and sponsored by Sheffield Teaching Hospitals NHS Foundation Trust, EXPERTS-ALS assesses potential therapies through a randomized, multicenter, open-label, multi-arm trial that evaluates investigational medicines through the measurement of the blood biomarker neurofilament light chain (NfL). NfL levels are significantly elevated in ALS patients due to accelerated neuroaxonal damage and correlate with the rate of disability progression and survival. Neflamapimod will be initially evaluated in approximately 35 participants with ALS for 18-24 weeks to determine its impact on NfL levels, with the potential for further evaluation in up to a total of 80 patients. Secondary and exploratory endpoints include several clinical and survival measures. “Neflamapimod is a promising investigational therapy for neurodegenerative diseases, and we’re excited to add it to the EXPERTS-ALS platform as we try to rapidly identify therapies that have the potential to slow disease progression in ALS,” said Chris McDermott, MBChB, FRCP, PhD, Professor of Translational Neurology, University of Sheffield. “The scientific rationale for neflamapimod's mechanism of action, combined with its positive clinical data in dementia with Lewy bodies, including a potent...